AVITA Medical Inc’s filing revealed that its Director McNamara Robert acquired Company’s shares for reported $91300.0 on Mar 06 ’25. In the deal valued at $8.30 per share,11,000 shares were bought. As a result of this transaction, McNamara Robert now holds 56,749 shares worth roughly $0.24 million.
Then, McNamara Robert bought 10,000 shares, generating $100,900 in total proceeds. Upon buying the shares at $10.09, the Director now owns 45,749 shares.
Before that, O’Toole David D bought 1,000 shares. AVITA Medical Inc shares valued at $9,900 were divested by the CFO at a price of $9.90 per share. As a result of the transaction, O’Toole David D now holds 25,734 shares, worth roughly $0.11 million.
BTIG Research downgraded its AVITA Medical Inc [RCEL] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including D. Boral Capital’s analysts, who began to cover the stock in late December with a ‘”a Buy”‘ rating. BTIG Research also remained covering RCEL and has decreased its forecast on April 11, 2024 with a “Neutral” recommendation from previously “Buy” rating. Cantor Fitzgerald started covering the stock on June 27, 2023. It rated RCEL as “an Overweight”.
Price Performance Review of RCEL
On Friday, AVITA Medical Inc [NASDAQ:RCEL] saw its stock fall -21.00% to $4.25. Over the last five days, the stock has lost -17.64%. AVITA Medical Inc shares have fallen nearly -47.34% since the year began. Nevertheless, the stocks have fallen -66.80% over the past one year.
How much short interest is there in AVITA Medical Inc?
A steep rise in short interest was recorded in AVITA Medical Inc stocks on 2025-07-15, growing by 1.22 million shares to a total of 5.71 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 4.49 million shares. There was a rise of 21.37%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 02, 2021 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $27 price target.
